Skip to content
Get the Balanced News app for a better experience!
The Balanced News Logo
Analytics
The Balanced News Logo

Stay Balanced, Stay Informed

Menu
  • Browse News
  • Underreported Stories
  • Curated Feeds
  • Insights
  • Analytics
  • Our Writers
  • About Us
  • Download App
Learn
  • How It Works
  • Bias Detection
  • Lens Score
  • Source Bias Checker
  • Accountability
  • Custom Feeds
Newsroom
  • Writers & Analysts
  • About TBN
  • Editorial Standards
  • Corrections Policy
  • Our Partners
  • Insights
Socials
  • Youtube
  • Instagram
  • X
  • Facebook
News Categories
  • Trending
  • Politics
  • Sports
  • Business
  • Tech
  • Entertainment
  • Health
  • Science
  • Crime
  • Lifestyle
  • National
  • International
  • Good News
  • Crypto

Get Our App

Available for iOS and Android


LensFeedsInsightsAnalyticsTrendingGood NewsSportsPoliticsBusinessCrimeTechEntertainmentHealthNationalInternational

© 2026 The Balanced News. All rights reserved.

About UsEditorial StandardsCorrectionsHelp & SupportPrivacy PolicyTerms & Conditions
Curis Lifesciences Reports Revenue Growth and Expands Portfolio, Enters Nigeria JV

Categories

Categories

Related Coverage

Select a news story to see related coverage from other media outlets.

Related Coverage

Select a news story to see related coverage from other media outlets.

  1. Home
  2. /
  3. Business

Curis Lifesciences Reports Revenue Growth and Expands Portfolio, Enters Nigeria JV

Analysed 16 Nov 2026·2 sources analysed·Nigeria·Business
Curis Lifesciences Reports Revenue Growth and Expands Portfolio, Enters Nigeria JVPreviousNext

Curis Lifesciences reported a 22.25% year-on-year revenue increase to INR 34.12 crore and a 52.84% half-on-half rise in profit after tax to INR 4.14 crore for H1 FY27. EBITDA grew 20.66% half-on-half with margin expansion. The company, through its 51%-owned subsidiary Uninova Lifesciences, is expanding its domestic branded pharmaceutical portfolio with plans to launch more products. Curis also entered a joint venture in Nigeria, holding a 49.5% stake to expand internationally.

Sentiment
75%
TBN's observations

First-hand measurement across 2 sources

We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (75/100). Lens Score 43/100.

Outlets measured: thetribune, thetribune. See how each one headlined and framed the same story in the source comparison below.

AI analysis of 2 sources · Published under editorial oversight by The Balanced News
Analysed 16 Nov 2026· How this analysis is produced· Editorial standards· Corrections

AI Analysis

Sentiment — Positive (75/100)

Sentiment was consistent across outlets (75–75/100), indicating broadly factual reporting rather than editorialising.

Coverage timeline

thetribune broke this story on 16 Nov, 04:53 am. Other outlets followed.

16 Nov, 04:53 am2 sources · 54 min16 Nov, 05:47 am
AI analysis by the TBN Bias Engine · beat methodology byMrunal Wange· Business & Economy Editor· editorial standards byOjas Kale
← Previous
Rediff.com India Files Rs 600 Crore IPO to Expand Digital and Enterprise Services
Next →
Morgan Stanley Forecasts Sensex Growth; NSE Market Cap Surpasses 5 Trillion Rupees
1
thetribune16 Nov, 04:53 am
Curis Lifesciences Reports 22 YoY Revenue Growth and 53 Sequential PAT Growth in H1 FY27; Expands Injectables Portfolio and Enters Nigeria
  • 2
    thetribune16 Nov, 05:47 am
    Curis Lifesciences Reports 22 YoY Revenue Growth and 53 Sequential PAT Growth in H1 FY27; Expands Injectables Portfolio and Enters Nigeria
  • Who's involved

    Institutions and figures named across source coverage.

    Corporate
    Euroson PharmaceuticalsCuris Lifesciences LimitedCuruson Pharmaceutical Nigeria Inc.Uninova Lifesciences

    Story context

    Category
    Business
    Location
    Nigeria
    Sources analysed
    2
    Last analysed
    16 Nov 2026
    Key entities
    Earnings before interest, taxes, depreciation, and amortizationRevenueCroreIndian rupeeNigeriaMedicationNet incomeEarnings per shareHydrogenIndiaBusiness WireJoint venture